Press Releases

28 Dec 2017 Cingulate Therapeutics to Present at 10th Annual Biotech Showcase

Kansas City, KS – (December 28, 2017) – Cingulate Therapeutics, LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery platform technology, today announced that Cingulate’s Chairman and Chief

15 Nov 2017 Cingulate Therapeutics to Present In Vivo Pharmacokinetic Data Demonstrating Consistent Tri-Phasic Release Profile of Lead Compound at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting

Kansas City, KS – (November 15, 2017) – Cingulate Therapeutics, LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing an innovative drug delivery platform technology, today announced the presentation of a poster titled, “Development and

08 Aug 2017 Cingulate Therapeutics Partners with Camargo Pharmaceutical Services for Development Programs

Kansas City, KS and Cincinnati, OH – (August 8, 2017) – Cingulate Therapeutics, LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit – Hyperactivity Disorder (ADHD), today announced that it has entered into

10 Jul 2017 Cingulate Therapeutics Appoints Strategic Finance Veteran Louis G. Van Horn as Chief Financial Officer

Kansas City, KS – (July 10, 2017) – Cingulate Therapeutics, LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), today announced the appointment of Louis G.

19 Jun 2017 Cingulate to Present at 2017 BIO International Convention

Kansas City, KS – (June 19, 2017) – Cingulate Therapeutics, LLC, a privately held biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), today announced that Shane J.

15 Jun 2017 Cingulate Therapeutics Announces Expansion to Accommodate Growth

Kansas City, KS – (June 15, 2017) – Cingulate Therapeutics, LLC, a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), today announced that it has moved the location